A Survey of the Protective Effect of Vitamin B6 on Linezolid-Associated Hematological Dyscrasia Vitamin B6 and linezolid hematological toxicities
Iranian Journal of Pharmaceutical Sciences,
Vol. 17 No. 2 (2021),
1 April 2021
,
Page 1-10
https://doi.org/10.22037/ijps.v17.40282
Abstract
Hematological toxicities are considerable side effects of linezolid, which can restrict its administration. This study aims to evaluate the protective effect of vitamin B6 on linezolid-induced hematological dyscrasia, i.e., thrombocytopenia and anemia in poisoned patients. In this quasi-experimental (non-randomized, non-blinded) study, a number of 28 patients treated with linezolid and vitamin B6 were matched with 50 patients who received only linezolid. The hematological factors, including red blood cells (RBCs), hemoglobin (Hb), hematocrit (Hct), and platelets (PLTs) were assessed at baseline and on days 0, 1, 3, 5, and 7 during the linezolid treatment coarse. There were no considerable differences between the two groups in demographic characteristics, poisoning, vital signs, baseline laboratory test results, and mortality rates. Overall, patients who received linezolid+B6 had significantly higher RBCs, Hb, and Hct than those treated with linezolid alone (P < 0.05). Unexpectedly, patients in the treatment group had lower PLT counts compared to the control group with no significant differences (P > 0.05). According to our findings, the co-administration of vitamin B6 and linezolid was accompanied by a lower risk of anemia but no impact on preventing or reducing thrombocytopenia in patients with gram-positive bacterial infections.
- Anemia
- Antibiotic
- Thrombocytopenia
- Nutritional supplement
- Gram-positive bacteria
- ICU
- Hematological dyscrasia
How to Cite
References
[2] Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. (2006) 34 (6): 1589-1596.
[3] Mittal G, Bhandari V, Gaind R, Rani V, Chopra S, et al. Linezolid resistant coagulase negative staphylococci (LRCoNS) with novel mutations causing blood stream infections (BSI) in India. BMC Infect. Dis. (2019) 19: 717-724.
[4] Bernstein WB, Trotta RF, Rector JT, et al. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann. Pharmacother. (2003) 37: 517-20.
[5] Rajan V, Kumar VGS, Gopal S. A cfr-positive clinical staphylococcal isolate from India with multiple mechanisms of linezolid-resistance. Indian J. Med. Res. (2014) 139: 463-467.
[6] Attassi K, Hershberger E, Alam R, et al. Thrombocytopenia associated with linezolid therapy. Clin. Infect. Dis. (2002) 34: 695-698.
[7] Im JH, Baek JH, Kwon HY, et al. Incidence and risk factors of linezolid-induced lactic acidosis. Int. J. Infect. Dis. (2015) 31: 47-52.
[8] Quinn DK, Stern TA. Linezolid and serotonin syndrome. Prim. Care Companion J. Clin. Psychiatry. (2009) 11: 353-356.
[9] Legout L, Senneville E, Gomel JJ, et al. Linezolid-induced neuropathy. Clin. Infect. Dis. (2004) 38: 767-768.
[10] Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J. Antimicrob. Chemother. (2013) 68 (9): 2128-2133.
[11] Garazzino S, De Rosa FG, Bargiacchi O, et al. Haematological safety of long-term therapy with linezolid. Int. J. Antimicrob. Agents. (2007) 29: 480-483.
[12] George JN, Aster RH. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology Am. Soc. Hematol. Educ. Program. (2019) 153-158.
[13] Hanai Y, Matsuo K, Ogawa M, Ayaka H, Kimura I, et al. A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia. J. Infect. Chemother. (2016) 22: 536-542.
[14] Tajima M, Kato Y, Matsumoto J, Hirosawa I, Suzuki M, Takashio Y, et al. Linezolid-induced thrombocytopenia is caused by suppression of platelet production via phosphorylation of myosin light chain 2. Biol. Pharm. Bull. (2016) 39: 1846-1851.
[15] Hirano R, Sakamoto Y, Tachibana N, Ohnishi M. Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients. Int. J. Clin. Pharm. (2014) 36 (4): 795-799.
[16] Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J. Antimicrob. Chemother. (2004) 54: 832-835.
[17] Leung LLK, Mentzer WC, Tirnauer JS, Approach to the adult with anemia. cited: Aug 5, 2020, available at: https://www.lib.utdo.ir/contents/approach-to-the-adult-withanemia/
[18] Marshall AL, Kenneth K, Josef TP, Marcel ML, Linda JB, James OA. Williams manual of hematology. 9th ed. McGraw-Hill Education/Medical, New York (2016) 672.
[19] Laurence L, Valette M, Dezeque H, Nguyen S, Lemaire X, et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?. J. Antimicrob. Chemother. (2010) 65: 2224-2230.
[20] Bickers JN, Brown L, Sprague CC. Pyridoxine responsive anemia. Blood. (1962) 19: 304-312.
[21] Spinneker A, Sola R, Lemmen V, Castillo MJ, Pietrzik K, González-Gross M. Vitamin B6 status, deficiency and its consequences-an overview. Nutr. Hosp. (2007) 22 (1): 7-24.
[22] Talaie H, Mousavizadeh A, Emami H, Gachkar L, Barari B, Alijanzadeh MH. High sensitivity versus low level of vancomycin needs to be concern for another alternative anti- Staphylococcus aureus as the first- line antibiotic. Acta Biomed. (2019) 90 (4): 506-511.
[23] Burnham JP, Burnham CA, Warren DK, Kollef MH. Impact of time to appropriate therapy on mortality in patients with vancomycin-intermediate Staphylococcus aureus infection. Antimicrob. Agents Chemother. (2016) 60 (9): 5546-5553.
[24] Lesher B, Gao X, Chen Y, Liu Z. Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of China. Clinicoecon Outcomes Res. (2016) 8: 63-72.
[25] Nukui Y, Hatakeyama S, Okamoto K, Yamamoto T, Hisaka A, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J. Antimicrob. Chemother. (2013) 68 (9): 2128-2133.
[26] Talaie H, Hosseini SM, Nazari M, Salavati-Esfahani M, Barari B. Risk Factors of Hospital-acquired Thrombocytopenia in Toxicological Intensive Care Unit. Int. J. Med. Toxicol. Forensic Med. (2020) 10 (3): 32256.
[27] Youssef S, Hachem R, Chemaly RF, Adachi J, Ying J, Rolston K, Raad I. The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. J. Antimicrob. Chemother. (2008) 61: 421-424.
[28] Deng J, Su L, Liang Z, Liang L, Yan P, Jia Y, Zhang X, Feng D, Xie L. Effects of Vitamin B6 Therapy for Sepsis Patients with Linezolid-Associated Cytopenias: A Retrospective Study. Curr. Ther. Res. Clin. Exp. (2013) 74: 26-32.
- Abstract Viewed: 544 times
- IJPS_Volume 17_Issue 2_Pages 1-10 Downloaded: 307 times